Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease
暂无分享,去创建一个
G. Pearlson | J. Brandt | E. Aylward | C. Ross | P. Barta | O. C. Stine | A. Rosenblatt | M. Sherr | A. Codori | O. Stine | Elizabeth H. Aylward | Ann Marie Codori | Oscar C. Stine
[1] R. Hichwa,et al. PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.
[2] S. Folstein,et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.
[3] K. Kieburtz,et al. Assessment of coenzyme q10 tolerability in huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[4] S. Fahn,et al. Huntington disease , 1979, Neurology.
[5] J. Brandt,et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.
[6] R. M. Stewart,et al. Evoked potentials in Huntington's disease. A comparative and longitudinal study. , 1984, Archives of neurology.
[7] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[8] G. Pearlson,et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.
[9] J. Brandt,et al. Trinucleotide repeat length and clinical progression in Huntington's disease , 1996, Neurology.
[10] M. MacDonald,et al. CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.
[11] Ira Shoulson,et al. Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals , 1990, Movement disorders : official journal of the Movement Disorder Society.
[12] Jane S. Paulsen,et al. Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.
[13] E. Aylward,et al. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). , 1997, Medicine.
[14] J C Mazziotta,et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.
[15] C A Ross,et al. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. , 1993, Human molecular genetics.
[16] Terry L. Jernigan,et al. Cerebral structure on MRI, part II: Specific changes in Alzheimer's and Huntington's diseases , 1991, Biological Psychiatry.
[17] D. Eidelberg,et al. [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.
[18] S. Folstein,et al. The diagnosis of Huntington's disease , 1986, Neurology.
[19] R. Roos,et al. Unified Huntington's disease rating scale: A follow up , 1998, Movement disorders : official journal of the Movement Disorder Society.
[20] P Boesiger,et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.
[21] S. Plumb,et al. A controlled clinical trial of baclofen as protective therapy in early huntington's disease , 1989, Annals of neurology.
[22] G. Pearlson,et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease , 1997, Neurology.
[23] Lisfrancm.. On the Treatment of White Tumors of the Joints , 1835 .
[24] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[25] M. Hayden,et al. Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.
[26] I. Shoulson,et al. A prospective evaluation of cognitive decline in early Huntington's disease , 1995, Neurology.
[27] I. Shoulson,et al. Experimental therapeutics of neurodegenerative disorders: unmet needs. , 1998, Science.
[28] R. Hichwa,et al. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. , 1995, Archives of neurology.
[29] K. Kieburtz,et al. Functional decline in Huntington's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.
[30] Jane S. Paulsen,et al. Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.
[31] J. Mazziotta,et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.
[32] J. Brandt,et al. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[33] E. Aylward,et al. Does CAG repeat number predict the rate of pathological changes in Huntington's disease? , 1998, Annals of neurology.
[34] R J Leigh,et al. The measurement of abnormal movement: methods developed for Huntington's disease. , 1983, Neurobehavioral toxicology and teratology.
[35] M. Hayden,et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease , 1987, Neurology.